Design, synthesis and biological evaluation of aminopyrimidine derivatives bearing dihydroquinoxalinone as novel EGFRL858R/T790M kinase inhibitors against non-small-cell lung cancer-Reference-Cited by-同舟云学术

Design, synthesis and biological evaluation of aminopyrimidine derivatives bearing dihydroquinoxalinone as novel EGFRL858R/T790M kinase inhibitors against non-small-cell lung cancer

Published:2023-04-21 Issue:6 Volume:32 Page:1130-1142
ISSN:1054-2523
Container-title:Medicinal Chemistry Research
language:en
Short-container-title:Med Chem Res

Author:

Fu Liping,Cao Yu,Chen Jingbai,He Ruoyu,Zhao Yanmei,Zhao Yaping,Xi Jianjun,Zhuang Rangxiao,Tian Chongmei

Funder

Zhejiang Province Public Welfare Technology Application Research Project

Medical health science and technology major project of Hangzhou Health Commission

Publisher

Springer Science and Business Media LLC

Subject

Organic Chemistry,General Pharmacology, Toxicology and Pharmaceutics

Link

https://link.springer.com/content/pdf/10.1007/s00044-023-03054-6.pdf

Reference31 articles.

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

2. Zhang YL, Yuan JQ, Wang KF, Fu XH, Tang JL. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7:78985–93.

3. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2014;19:3159–67.

4. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7:169–81.

5. Gazdar AF, Minna JD. Inhibition of EGFR signaling: all mutations are not created equal. PLoS Med. 2005;2:e377.